Market Overview

UPDATE: Canaccord Genuity Raises PT to $12.50 on Sunshine Heart Following Pivotal Trial Approval

Related SSH
Sunshine Heart Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Sunshine Heart Names Eric Lovett as VP, Clinical Affairs

Canaccord Genuity reiterated its Buy rating on Sunshine Heart (NASDAQ: SSH) and raised its price target from $11 to $12.50.

Canaccord Genuity noted, " Sunshine Heart received FDA conditional approval for the C-Pulse pivotal trial. As expected, the trial will enroll 388 Class III/IV HF patients randomized to either C-Pulse or optimal medical therapy at 30-40 centers. … In addition, SSH has been granted approval to sell C-Pulse into the trial. We're maintaining our F2012 estimates, as it can take several months for centers to receive IRB approval prior to enrolling patients. That said, we believe it's possible the company could start booking revenue this quarter."

Sunshine Heart closed at $8.75 on Friday.

Latest Ratings for SSH

Mar 2016OppenheimerDowngradesOutperformPerform
Mar 2015Cowen & CompanyMaintainsOutperform
Mar 2015OppenheimerMaintainsOutperform

View More Analyst Ratings for SSH
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (SSH)

View Comments and Join the Discussion!